Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 1082

1.

Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.

Midha KK, Hubbard JW, Marder SR, Marshall BD, Van Putten T.

J Psychiatry Neurosci. 1994 Jul;19(4):254-64. Review.

2.

Clinical perspectives of some neuroleptics through development and application of their assays.

Midha KK, Marder SR, Jaworski TJ, McKay G, Hubbard JW, Hawes EM, Van Putten T, Wirshing WC, Aravagiri M.

Ther Drug Monit. 1993 Jun;15(3):179-89. Review.

PMID:
8101398
3.

Monitoring plasma levels of fluphenazine during chronic therapy with fluphenazine decanoate.

Miller RS, Peterson GM, McLean S, Westhead TT, Gillies P.

J Clin Pharm Ther. 1995 Apr;20(2):55-62.

PMID:
7650075
4.

A practical loading dose method for converting schizophrenic patients from oral to depot haloperidol therapy.

Wei FC, Jann MW, Lin HN, Piao-Chien C, Chang WH.

J Clin Psychiatry. 1996 Jul;57(7):298-302.

PMID:
8666571
5.

[Erythrocyte ketone reductase activity, total plasma haloperidol and acute psychoses].

Dutoit D, Thomas P, Leroux JM, Vaiga G, Pommery J, Cottencin O, Erb F, Goudemand M.

Encephale. 1995 Nov-Dec;21(6):417-24. French.

PMID:
8674466
6.

Plasma levels of fluphenazine in patients receiving fluphenazine decanoate. Relationship to clinical response.

Marder SR, Midha KK, Van Putten T, Aravagiri M, Hawes EM, Hubbard JW, McKay G, Mintz J.

Br J Psychiatry. 1991 May;158:658-65.

PMID:
1860020
7.

Haloperidol decanoate v. fluphenazine decanoate as maintenance therapy in chronic schizophrenic in-patients.

McKane JP, Robinson AD, Wiles DH, McCreadie RG, Stirling GS.

Br J Psychiatry. 1987 Sep;151:333-6.

PMID:
3322467
8.

Neuroleptic plasma levels.

Van Putten T, Marder SR, Wirshing WC, Aravagiri M, Chabert N.

Schizophr Bull. 1991;17(2):197-216. Review.

PMID:
1679251
9.

Fluphenazine levels during maintenance treatment of recent-onset schizophrenia: relation to side effects, psychosocial function and depression.

Gitlin MJ, Nuechterlein KH, Mintz J, Fogelson D, Bartzokis G, Ventura J, Subotnik K, Aravagiri M.

Psychopharmacology (Berl). 2000 Mar;148(4):350-4.

PMID:
10928306
10.
11.

A randomized clinical trial of haloperidol decanoate and fluphenazine decanoate in the outpatient treatment of schizophrenia.

Chouinard G, Annable L, Campbell W.

J Clin Psychopharmacol. 1989 Aug;9(4):247-53.

PMID:
2570086
12.

Reduced haloperidol does not interfere with the antipsychotic activity of haloperidol in the treatment of acute schizophrenia.

Ulrich S, Neuhof S, Braun V, Meyer FP.

Int Clin Psychopharmacol. 1999 Jul;14(4):219-28.

PMID:
10468314
13.

A loading-dose strategy for converting from oral to depot haloperidol.

Ereshefsky L, Toney G, Saklad SR, Anderson C, Seidel D.

Hosp Community Psychiatry. 1993 Dec;44(12):1155-61.

PMID:
7907570
14.

Plasma levels of neuroleptic in patients receiving depot fluphenazine.

Cohen BM, Waternaux C, Chouinard G, Sommer BR, Jones B.

J Clin Psychopharmacol. 1985 Dec;5(6):328-32.

PMID:
4066997
16.
17.

Plasma fluphenazine levels and clinical response in newly admitted schizophrenic patients.

Van Putten T, Aravagiri M, Marder SR, Wirshing WC, Mintz J, Chabert N.

Psychopharmacol Bull. 1991;27(2):91-6.

PMID:
1924666
18.
19.

[Clinical and economic approach to evaluation of the effectiveness of moditen-depot and haloperidol decanoate in the maintenance therapy of attack-like schizophrenia].

Ushakov IuV, Kravchenko NE, Kopeĭko GI, Kalugina LI, Mirzoian MG.

Zh Nevropatol Psikhiatr Im S S Korsakova. 1990;90(7):99-104. Russian.

PMID:
1979463
20.

Correlation of fluphenazine plasma levels versus clinical response in patients: a pilot study.

Dudley J, Rauw G, Hawes EM, Keegan DL, Midha KK.

Prog Neuropsychopharmacol Biol Psychiatry. 1983;7(4-6):791-5.

PMID:
6686710

Supplemental Content

Support Center